Literature DB >> 1962854

WHO International Histological Classification of Tumours. Tentative Histological Classification of Salivary Gland Tumours.

G Seifert1, C Brocheriou, A Cardesa, J W Eveson.   

Abstract

The principles of the proposed modified WHO Histological Typing of Salivary Gland Tumours are based on the following: 1) The classification of tumours is oriented to the routine work of the practicing surgical pathologists, those who do not see tumours of the salivary glands very often. The inclusion of rare, but clearly defined tumour entities should be helpful to surgical pathologists consulting with clinical specialists. 2) The different types of carcinomas must be distinguished not only by precise histopathological definitions, but also considering differences in prognosis and treatment. For example, the polymorphous low-grade adenocarcinoma and the epithelial-myoepithelial carcinoma are characterized by a relatively good prognosis in contrast to the salivary duct carcinoma. 3) Special points of discussion are: subclassification and grading of carcinomas (e.g. acinic cell carcinoma, mucoepidermoid carcinoma and adenoid cystic carcinoma), the classification of basal cell tumours (basal cell adenoma, basal cell carcinoma, solid type of adenoid cystic carcinoma), malignant tumours in pleomorphic adenomas and the differential diagnosis between primary tumours and metastases.

Entities:  

Mesh:

Year:  1990        PMID: 1962854     DOI: 10.1016/S0344-0338(11)80220-7

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  51 in total

1.  [Rare malignant tumor of the parotid gland. Myoepithelial carcinoma].

Authors:  F Haubner; H G Gassner; F Eder; U Müller-Vogt
Journal:  HNO       Date:  2010-11       Impact factor: 1.284

Review 2.  Troublesome tumours 2: borderline tumours of salivary glands.

Authors:  J W Eveson
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

3.  Primary ductal adenocarcinoma of the lacrimal gland.

Authors:  Yoon Jung Lee; Young-Ha Oh
Journal:  Jpn J Ophthalmol       Date:  2009-05-31       Impact factor: 2.447

4.  A rare malignancy of the parotid gland: oncocytic carcinoma.

Authors:  Ender Guclu; Fatih Oghan; Ozcan Ozturk; Murat Alper; Erol Egeli
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-12-09       Impact factor: 2.503

Review 5.  Basal cell adenoma of nasal septum: report of a case and review of literature.

Authors:  Qinying Wang; Haihong Chen; Shenqing Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 6.  Salivary gland-like tumours of the breast: surgical and molecular pathology.

Authors:  M Pia-Foschini; J S Reis-Filho; V Eusebi; S R Lakhani
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

7.  Epigenetic screening of salivary gland mucoepidermoid carcinoma identifies hypomethylation of CLIC3 as a common alteration.

Authors:  Zhiming Wang; Shizhang Ling; Eleni Rettig; Ryan Sobel; Marietta Tan; Elana J Fertig; Michael Considine; Adel K El-Naggar; Mariana Brait; Carole Fakhry; Patrick K Ha
Journal:  Oral Oncol       Date:  2015-10-17       Impact factor: 5.337

8.  Immunoreactivity of proliferating cell nuclear antigen in salivary gland tumours: an assessment of growth potential.

Authors:  L Yang; K Hashimura; C Qin; P Shrestha; S Sumitomo; M Mori
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

9.  Argyrophilia in nucleolar organizer regions (AgNOR) in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of the salivary glands.

Authors:  R A Freitas; V C de Araújo; N S Araújo
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

10.  Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

Authors:  S J Wong; T Karrison; D N Hayes; M S Kies; K J Cullen; T Tanvetyanon; A Argiris; N Takebe; D Lim; N F Saba; F P Worden; J Gilbert; H J Lenz; A R A Razak; J D Roberts; E E Vokes; E E W Cohen
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.